-bluebird (BLUE): updates from Phase I/II LentiGlobin studies (HGB-204/Northstar and HGB-205) in beta-thal
-Epizyme (EPZM): additional preclinical and Ph 1 data of EPZ-5676 and potential top-line Ph 1 data of EPZ-6438
-Foundation Medicine (FMI): additional FoundationOne publications likely to be presented
-Karyopharm (KPTI): additional data of Selinexor in multiple myeloma and non-Hodgkin's lymphoma
-MEI (MEIP): data from Ph 2 pracinostat/Vidaza combo study in elderly AML
Pharmacyclics (PCYC): data from studies of Imbruvica in del17p r/r CLL/SLL, follicular lymphoma and MM Stemline (STML): preclinical data for SL-401, SL-501 and SL-101 Xencor (XNCR): data from Ph 2 trials of XmAb5574/MOR208 in ALL and NHL
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.